CRISPR, the gene-editing technology, has been one of the major breakthroughs in biology in the last two decades. And while ...

News about biofuels sometimes mentions used cooking oil as a feedstock, but if these substances contain animal fat, they can ...

CRISPR Therapeutics' (NASDAQ: CRSP) stock may be down by 21% this year so far, but that doesn't mean you should write it off ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow ...

CRISPR Therapeutics has experienced a 21% decline in its stock value this year. Despite this drop, the biotech company ...

UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara co-present Dr. Jennifer Doudna, CRISPR Gene Editing and the ...

CREME is a virtual laboratory that allows scientists to simulate specific decreases in gene activity. It offers a powerful new tool for identifying and understanding important parts of the genome. And ...

The future of CRISPR involves clinical trials focused on treatment for blood diseases and cancers, cardiovascular disease, ...

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

Benjamin Sodey, a former in-house lawyer at life sciences business MilliporeSigma, says he's looking forward to growing his ...